We have established several companies to facilitate research translation and to promote collaboration.

Genera Biosystems Limited

An Australian publicly listed company (ASX: GBI) that develops and commercialises multiplexed molecular diagnostic tests, based upon its proprietary AmpaSandTM bead-based technology. Genera’s first product on sale is PapTypeTM, a highly competitive molecular diagnostic test for the simultaneous detection and genotyping of the 14 high-risk types of human papillomavirus (HPV). Genera has also submitted to the TGA its new test, RTIplex, a multiplexed test for 15 pathogens of the upper respiratory tract. The company has a number of other products in its development pipeline.

MuriGen Therapeutics Limited

An Australian based drug discovery and development company building a portfolio of novel drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia and inflammation. By leveraging its proprietary drug discovery platform, MuriGen Therapeutics is working towards the validation of novel drug targets that have the potential to provide significant benefits for researchers, health care practitioners, and patients.

ImmusanT

ImmusanT is an early stage biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with coeliac disease.

ImmusanT’s treatment is an immune tolerising therapy using a series of peptides that target the common genetic form of coeliac disease. This peptide-based immunotherapy is designed to tolerise the patient’s immune system to toxic gluten peptides.

Catalyst Therapeutics

Catalyst Therapeutics Pty Ltd, founded in 2012, is an investment and project management company formed by a partnership between the Walter and Eliza Hall Institute of Medical Research and SYNthesis med chem Pty Ltd. The mission is to create value by catalysing proof-of-concept and accelerating translation through early stage discovery.